EN001 Placebo

DRUG2 trials

Sponsors

ENCell

Conditions

Charcot-Marie-Tooth Disease Type 1ASarcopenia

Phase 1

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

RecruitingNCT06328712

ENCellCharcot-Marie-Tooth Disease Type 1A

Start: 2024-05-30End: 2026-12-31Target: 27Updated: 2026-05-26

Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia

Not yet recruitingNCT07808905

ENCellSarcopenia

Start: 2027-03-01End: 2029-10-31Target: 132Updated: 2026-09-11